{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-003208","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.175453+00:00","generated_at":"2026-05-28T01:45:19.324625+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cellectar reports iopofosine 83.6% ORR in WM; plans confirmatory study for accelerated approval","bullets":["Iopofosine I 131 achieved 83.6% ORR and 58.2% MRR in Phase 2 CLOVER-WaM for Waldenstrom's Macroglobulinemia; primary endpoint of 20% MRR exceeded.","Company expects confirmatory randomized study (40-60 patients/arm) with FDA alignment in H1 2025; cash runway through Q4 2025.","Advancing alpha-emitting PRC CLR 121225 into Phase 1/2a solid tumor studies; IND filing expected Q1 2025.","Auger-emitting PRC CLR 121125 IND cleared; Phase 1b/2a dose finding study in triple-negative breast cancer planned.","Company pursuing partnerships for iopofosine; presentation at Biotech Showcase on Jan 14, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-003208","json":"https://secwatch.observer/filing/0001104659-25-003208.json","markdown":"https://secwatch.observer/filing/0001104659-25-003208.md","text":"https://secwatch.observer/filing/0001104659-25-003208.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925003208/0001104659-25-003208-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925003208/tm253236d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:45:19.324625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}